An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Conditions: Chronic Kidney Disease; Type 2 Diabetes Mellitus
Interventions: Drug: Finerenone (Kerendia, BAY 948862); Drug: Sodium-glucose cotransporter 2 inhibitors (SGLT2i); Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA); Drug: Steroidal mineral corticoid receptor antagonists (sMRA); Drug: Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Sponsors: Bayer
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.